Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
MRK: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; Drug pricing and reimbursement issues; Vaccine issues; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agen
Public: Oct 20, 2026, 5:25 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug prici
Public: Oct 20, 2026, 5:02 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to vaccines; Issues related to 340b Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Public: Oct 20, 2026, 3:59 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Education around access to vaccines. Issues around drug pricing.
Public: Oct 19, 2026, 11:51 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs.
Public: Oct 19, 2026, 6:35 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to intellectual property protections. Issues related to immunization policy. Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Public: Oct 19, 2026, 6:33 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
340B Program. Issues related to drug pricing. General pharmaceutical issues. Pubic health issues. Issues related to MFN. Appropriations and budget legislation for FY27. Reconciliation. Issues related to supply chain and shortages. Issues on vaccine policy. PBM reform. FDA issues. IRA Implementation. Issues related to Medicare Part B and D. Issues related to Medicaid Drug Rebate Program (MDRP).
Public: Oct 19, 2026, 8:30 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medic
Public: Oct 17, 2026, 5:51 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to IRC sections 11, 951A, and 250.
Public: Oct 16, 2026, 1:13 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: Leadership change
Filed 8-K for an event or period dated 2026-10-09. Leadership change.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: third_quarter 2026 lobbying report
Issues related to corporate and international tax
Public: Oct 8, 2026, 2:44 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: Financial results
Filed 8-K for an event or period dated 2026-08-04. Financial results.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864: HELP Copays Act.
Public: Jul 20, 2026, 8:22 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues. Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implem
Public: Jul 20, 2026, 3:13 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
Education around access to vaccines. Issues related to drug pricing.
Public: Jul 20, 2026, 2:41 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
Issues related to vaccines; Issues related to 340b Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Public: Jul 20, 2026, 2:15 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pr
Public: Jul 20, 2026, 11:40 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs.
Public: Jul 20, 2026, 9:35 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026. Issues related to intellectual property protections. Issues related to immunization policy.
Public: Jul 19, 2026, 4:16 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: second_quarter 2026 lobbying report
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemi
Public: Jul 17, 2026, 11:08 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: 8-K company filing
Filed 8-K for an event or period dated 2026-05-26. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
MRK: Other company developments
Filed 8-K for an event or period dated 2026-05-22. Other company developments.
2 congressional households disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 7:56 AM EST
- USAspending
- Collection in progress129 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 7:47 AM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 6:27 AM EST
- Federal Register
- Collection in progress298 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 7:47 AM EST
- Regulations.gov
- Partial coverage — some requests unavailable27 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 7:47 AM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST